2 Tricks and a Treat for Gene Therapy Investors
The biotech sector has lagged the market since the start of 2021, with the iShares Biotech ETF up less than 3% compared to the 17% gains seen by the S&P 500 over the same time frame. This year has been especially tough on the gene therapy market.
While some companies produced lackluster results, others had clinical trials placed on hold, causing the sector to lag the market. Let's examine two ghastly gene therapy performers this year and one for investors to take a closer look at.
Image source: Getty Images.
Source Fool.com
